ATE453714T1 - Antigene aus cryptosporidium parvum, antikörper dagegen und diagnostische und therapeutische zusammensetzungen - Google Patents

Antigene aus cryptosporidium parvum, antikörper dagegen und diagnostische und therapeutische zusammensetzungen

Info

Publication number
ATE453714T1
ATE453714T1 AT06011952T AT06011952T ATE453714T1 AT E453714 T1 ATE453714 T1 AT E453714T1 AT 06011952 T AT06011952 T AT 06011952T AT 06011952 T AT06011952 T AT 06011952T AT E453714 T1 ATE453714 T1 AT E453714T1
Authority
AT
Austria
Prior art keywords
therapeutic compositions
diagnostic
antigens
antibodies against
cryptosporidium parvum
Prior art date
Application number
AT06011952T
Other languages
English (en)
Inventor
J Neil Simonsen
Original Assignee
Univ Manitoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manitoba filed Critical Univ Manitoba
Application granted granted Critical
Publication of ATE453714T1 publication Critical patent/ATE453714T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT06011952T 2000-06-15 2001-06-15 Antigene aus cryptosporidium parvum, antikörper dagegen und diagnostische und therapeutische zusammensetzungen ATE453714T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21208300P 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
ATE453714T1 true ATE453714T1 (de) 2010-01-15

Family

ID=22789489

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06011952T ATE453714T1 (de) 2000-06-15 2001-06-15 Antigene aus cryptosporidium parvum, antikörper dagegen und diagnostische und therapeutische zusammensetzungen
AT01944811T ATE407209T1 (de) 2000-06-15 2001-06-15 Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01944811T ATE407209T1 (de) 2000-06-15 2001-06-15 Cryptosporidium parvum antigene, deren antikörper und deren diagnostische und medische verbindungen

Country Status (8)

Country Link
US (4) US6808900B2 (de)
EP (2) EP1762620B1 (de)
AT (2) ATE453714T1 (de)
AU (1) AU6720601A (de)
CA (1) CA2411949C (de)
DE (2) DE60135655D1 (de)
ES (1) ES2313962T3 (de)
WO (1) WO2001096370A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
PL2371383T3 (pl) 2005-12-29 2016-01-29 Boehringer Ingelheim Vetmedica Inc Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
US20080226669A1 (en) 2005-12-29 2008-09-18 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
WO2008073464A2 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
ES2625460T5 (es) * 2006-12-15 2020-11-04 Boehringer Ingelheim Animal Health Usa Inc Tratamiento de cerdos seropositivos en anticuerpo anti-PCV2 con antígeno de PCV2
EP1941903A1 (de) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxe und Behandlung von PRDC
EP1958644A1 (de) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Vorbeugung und Behandlung von subklinischer PCVD
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
BRPI0821456A2 (pt) * 2007-12-31 2015-06-16 Boehring Ingelheim Vetmedica Inc Partícula similar à pcv2 orf2 com inserção de aminoácido estranho
EP2242511A4 (de) 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed Immunogene pcv2-zusammensetzungen gegen mycoplasma hyopneumoniae und verfahren zur herstellung solcher zusammensetzungen
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
CN103503841B (zh) * 2013-09-29 2016-01-20 捷胜海洋装备股份有限公司 一种浮球牵引机的牵引结构
DK3052516T3 (da) 2013-10-02 2020-03-23 Boehringer Ingelheim Animal Health Usa Inc PCV2-ORF2-proteinvariant og viruslignende partikler sammensat deraf

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993024649A1 (en) 1992-05-29 1993-12-09 The Regents Of The University Of California Cryptosporidium polypeptides, nucleic acid, vectors and methods of use
ATE195347T1 (de) * 1992-10-02 2000-08-15 Res Corp Technologies Inc Methoden der erhöhung der sekretion von überexpremierten proteinen
US5591434A (en) 1993-05-26 1997-01-07 The United States Of America As Represented By The Secretary Of Agriculture DNA sequence encoding surface protein of cryptosporidium parvum
AU740141B2 (en) * 1996-08-23 2001-11-01 Arizona Board Of Regents On Behalf Of The University Of Arizona, The Neutralization-sensitive epitopes of cryptosporidium parvum

Also Published As

Publication number Publication date
WO2001096370A3 (en) 2003-01-03
US7850972B2 (en) 2010-12-14
US6808900B2 (en) 2004-10-26
WO2001096370A9 (en) 2002-09-19
CA2411949A1 (en) 2001-12-20
DE60140972D1 (de) 2010-02-11
ES2313962T3 (es) 2009-03-16
US7288621B2 (en) 2007-10-30
US20120045464A1 (en) 2012-02-23
AU6720601A (en) 2001-12-24
US20020034516A1 (en) 2002-03-21
EP1294889A2 (de) 2003-03-26
EP1762620A3 (de) 2007-04-04
DE60135655D1 (de) 2008-10-16
US8241871B2 (en) 2012-08-14
EP1762620B1 (de) 2009-12-30
ATE407209T1 (de) 2008-09-15
US20050064553A1 (en) 2005-03-24
WO2001096370A2 (en) 2001-12-20
EP1294889B1 (de) 2008-09-03
CA2411949C (en) 2012-05-22
EP1762620A2 (de) 2007-03-14
US20080299143A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
ATE453714T1 (de) Antigene aus cryptosporidium parvum, antikörper dagegen und diagnostische und therapeutische zusammensetzungen
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
LTPA2020001I1 (lt) Anti-IL-12 antikūnai, kompozicijos, būdai ir panaudojimas Krono patologijai gydyti
AU5810201A (en) Immunogenic polypeptides encoded by mage minigenes and uses thereof
DE69637642D1 (de) Und kombinierte zusammensetzungen und deren verwendung
SI1317479T1 (sl) Postopki in sestavki za bolezni, povezane z amiloidozo
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
CY1108387T1 (el) Ανταγωνιστες ανασυνδυασμενης il-18 χρησιμοι στη θεραπεια παθησεων που εμφανιζονται με διαμεσολαβηση της il-18
ATE442866T1 (de) Fusionsproteine aus mycobakterium tuberculosis
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
ATE476196T1 (de) Zusammensetzung zur auslösung, verbesserung und erhaltung von immunantworten gegen mhc-klasse-i- beschränkte epitope, für prophylaktische oder therapeutische zwecke
DE60027890D1 (de) Streptococcus pneumoniae proteine und impfstoffe
DK2054431T3 (da) Konformere af bakterielle adhæsiner
WO2005007673A3 (en) Immunogenic peptides
DE60042816D1 (de) T-helferzellen-epitope
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
BR0113099A (pt) Gene e proteìna relacionados com esquizofrenia
ATE372129T1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
ATE543906T1 (de) Antigen von streptococcus aus der b-gruppe
DE60043499D1 (de) Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
ATE414154T1 (de) Moraxella (branhamella) catarrhalis antigene
ATE421586T1 (de) Moraxella (branhamella) catarrhalis antigene
ATE382365T1 (de) Thymosin-augmentation bei genetischer immunisierung
WO1999027955A3 (en) Treatment of established chronic infections and cancers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties